Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors
- Conditions
- Advanced/Metastatic Solid Tumors
- Interventions
- Drug: ADG206
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Adagene Inc
- Target Recruit Count
- 21
- Registration Number
- NCT05614258
- Locations
- 🇦🇺
Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia
🇦🇺Monash Health, Clayton, Victoria, Australia
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- Conditions
- Advanced/Metastatic Solid Tumors
- Interventions
- Drug: ADG126
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Adagene Inc
- Target Recruit Count
- 131
- Registration Number
- NCT05405595
- Locations
- 🇺🇸
Florida cancer specialist, Sarasota, Florida, United States
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Keimyung University Dongsan Hospital, Daegu, Korea, Republic of
ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- Conditions
- Advanced/Metastatic Solid Tumors
- Interventions
- Drug: ADG116
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Adagene Inc
- Target Recruit Count
- 6
- Registration Number
- NCT05277402
- Locations
- 🇺🇸
Carolina BioOncology Institute, Huntersville, North Carolina, United States
🇺🇸Next Oncology, San Antonio, Texas, United States
ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors
- Conditions
- Advanced/Metastatic Solid Tumors
- Interventions
- Biological: ADG126 MonoBiological: ADG126-anti PD1Biological: ADG126-ADG106
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Adagene Inc
- Target Recruit Count
- 58
- Registration Number
- NCT04645069
- Locations
- 🇦🇺
One Clinical Research Pty Ltd, Nedlands, Western Australia, Australia
🇦🇺Macquarie University Hospital, Sydney, New South Wales, Australia
🇦🇺Sunshine Coast University Private Hospital, Birtinya, Queensland, Australia
A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients
- Conditions
- Advanced/Metastatic Solid Tumors
- Interventions
- Drug: ADG116Drug: ADG106Drug: anti PD1 drug
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Adagene Inc
- Target Recruit Count
- 72
- Registration Number
- NCT04501276
- Locations
- 🇺🇸
Next Oncology, San Antonio, Texas, United States
🇦🇺Macquarie University, Sydney, Australia
🇦🇺Cabrini Hospital, Malvern, Australia
Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors
- Conditions
- Solid Tumor
- Interventions
- Drug: ADG116
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2021-09-10
- Lead Sponsor
- Adagene Inc
- Target Recruit Count
- 1
- Registration Number
- NCT04111445
- Locations
- 🇺🇸
NEXT Oncology, San Antonio, Texas, United States
Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
- Conditions
- Solid Tumors, Non-Hodgkin Lymphoma
- Interventions
- Drug: ADG106
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Adagene Inc
- Target Recruit Count
- 49
- Registration Number
- NCT03707093
- Locations
- 🇺🇸
Horizon Oncology Research, Lafayette, Indiana, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States